All In Biotech

Drug Trial Radar · NCT06154837

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

127

Actual

Start

Nov 27, 2023

Primary completion

Dec 16, 2026

Study completion Dec 16, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • GSK3862995BDrug

    GSK3862995B will be administered.

  • PlaceboDrug

    Placebo will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 36 weeks
  2. Part B: Number of Participants with AEs and SAEsTime frame: Up to 48 weeks
  3. Part A: Number of Participants with Clinically significant changes in laboratory valuesTime frame: Up to 28 weeks
  4. Part A: Number of Participants with Clinically Significant Change in vital signsTime frame: Up to 28 weeks
  5. Part A: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) ParametersTime frame: Up to 28 weeks
  6. Part B: Number of Participants with Clinically significant changes in laboratory values (haematology, chemistry and urinalysis)Time frame: Up to 42 weeks
  7. Part B: Number of Participants with Clinically Significant Change in vital signsTime frame: Up to 42 weeks
  8. Part B: Number of Participants with Clinically Significant Change in 12-lead Electrocardiogram (ECG) ParametersTime frame: Up to 42 weeks

Locations

31 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Yuma, Arizona

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Orange City, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Columbus, Georgia

  • GSK Investigational Site

    Shelby, North Carolina

  • GSK Investigational Site

    Medford, Oregon

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Rock Hill, South Carolina

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Ahrensburg, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Dresden, Germany

  • GSK Investigational Site

    Frankfurt, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Leipzig, Germany

  • GSK Investigational Site

    Lübeck, Germany

  • GSK Investigational Site

    Mainz, Germany

  • GSK Investigational Site

    Hanover, Lower Saxony, Germany

  • GSK Investigational Site

    Schwerin, Mecklenburg-Vorpommern, Germany

  • GSK Investigational Site

    Barnsley, United Kingdom

  • GSK Investigational Site

    Cambridge, United Kingdom

  • GSK Investigational Site

    Cannock, United Kingdom

  • GSK Investigational Site

    London, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    West Yorkshire, United Kingdom

  • GSK Investigational Site

    Blackpool, Lancashire, United Kingdom

  • GSK Investigational Site

    Harrow, Middlesex, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.